{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T19:54:06Z","timestamp":1762458846432},"reference-count":17,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1016\/j.jacl.2011.01.002","type":"journal-article","created":{"date-parts":[[2011,1,20]],"date-time":"2011-01-20T09:31:12Z","timestamp":1295515872000},"page":"114-119","source":"Crossref","is-referenced-by-count":2,"title":["Persistent erythema with niacin is not attributable to aspirin resistance"],"prefix":"10.1016","volume":"5","author":[{"given":"Michael J.","family":"Babcock","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aneysa C.","family":"Sane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delrae M.","family":"Eckman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David C.","family":"Sane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2011.01.002_bib1","first-page":"32C","article-title":"Safety considerations with niacin therapy","volume":"99","author":"Gupton","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2011.01.002_bib2","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/1523-1747.ep12499963","article-title":"Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans","volume":"98","author":"Morrow","year":"1992","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jacl.2011.01.002_bib3","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.1172\/JCI23626","article-title":"GPR109A (PVMA-G\/HM74A) mediates nicotinic acid-inducing flushing","volume":"115","author":"Benyo","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jacl.2011.01.002_bib4","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1124\/mol.106.030833","article-title":"Nicotinic acid-induced flushing is mediated by activation of epidermal Langerhans cells","volume":"70","author":"Benyo","year":"2006","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.jacl.2011.01.002_bib5","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1038\/sj.jid.5700586","article-title":"Langerhans cells release prostaglandin D2 in response to nicotinic acid","volume":"126","author":"Maciejewski-Lenoir","year":"2006","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jacl.2011.01.002_bib6","doi-asserted-by":"crossref","first-page":"6682","DOI":"10.1073\/pnas.0601574103","article-title":"Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans","volume":"103","author":"Cheng","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jacl.2011.01.002_bib7","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/sj.clpt.6100180","article-title":"Suppression of Niacin-Induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1","volume":"81","author":"Lai","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jacl.2011.01.002_bib8","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/j.1368-5031.2006.00957.x","article-title":"Clinical evidence for use of acetyl salicylic acid in control of flushing related to nicotinic acid treatment","volume":"60","author":"Oberwittler","year":"2006","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jacl.2011.01.002_bib9","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1136\/bmj.39430.529549.BE","article-title":"Aspirin \u201cresistance\u201d and risk of cardiovascular morbidity: systematic review and meta-analysis","volume":"336","author":"Krasopoulos","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.jacl.2011.01.002_bib10","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1479-5876-6-47","article-title":"\u2018Aspirin resistance\u2019 or treatment non-compliance: which is to blame for cardiovascular complications?","volume":"6","author":"Shantsila","year":"2008","journal-title":"J\u00a0Trasnlational Med"},{"key":"10.1016\/j.jacl.2011.01.002_bib11","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1161\/CIRCULATIONAHA.109.900589","article-title":"Association of cyclooxygenase-1\u2212dependent and \u2013independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization","volume":"120","author":"Frelinger","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2011.01.002_bib12","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0920-9964(97)00100-X","article-title":"Niacin skin flush in schizophrenia: a preliminary report","volume":"29","author":"Ward","year":"1998","journal-title":"Schizophrenia Res"},{"key":"10.1016\/j.jacl.2011.01.002_bib13","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0022-3956(03)00006-2","article-title":"Potential use of the topical niacin skin test in early spectroscopy and a descriptive rating scale","volume":"37","author":"Smesny","year":"2003","journal-title":"J Psychiatric Res"},{"key":"10.1016\/j.jacl.2011.01.002_bib14","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.plefa.2003.08.013","article-title":"Relationship between the niacin skin flush response and essential fatty acids in schizophrenia","volume":"69","author":"Messamore","year":"2003","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"10.1016\/j.jacl.2011.01.002_bib15","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.psychres.2006.10.002","article-title":"Absent response to niacin skin patch is specific to schizophrenia and independent of smoking","volume":"152","author":"Liu","year":"2007","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.jacl.2011.01.002_bib16","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.psychres.2005.10.010","article-title":"Niacin skin flushing in schizophrenic and depressed patients and healthy controls","volume":"143","author":"Bosveld-van Haandel","year":"2006","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.jacl.2011.01.002_bib17","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1124\/jpet.108.141333","article-title":"Niacin-induced \u201cflush\u201d involves release of prostaglandin D2 from mast cells and serotonin from platelets: evidence from human cells in vitro and an animal model","volume":"327","author":"Papaliodis","year":"2008","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287411000183?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287411000183?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,5]],"date-time":"2018-12-05T11:24:48Z","timestamp":1544009088000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287411000183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["S1933287411000183"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2011.01.002","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3]]}}}